Mary Adewunmi

Mary Adewunmi

Auto-generated profile, based on publicly available information

Mary Adewunmi

Charles Darwin University 27 Menzies School of Health Research Darwin, Australia

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2024 in Cancer Reports
Verified
Journal Article
Open access
OAOluwatosin Maryam Adeyemo
Oluwatosin Maryam Adeyemo
ZAZainab Ashimiyu‐Abdusalam
Zainab Ashimiyu‐Abdusalam
MAMary Adewunmi
Mary Adewunmi
TATemitope Ayanfunke Ayano
Temitope Ayanfunke Ayano
MSMuhammad Sohaib
Muhammad Sohaib
RAReem Abdel‐Salam
Reem Abdel‐Salam
Background: NSCLC is a lethal cancer that is highly prevalent and accounts for 85% of cases of lung cancer. Conventional cancer treatments, such as chemotherapy and radiation, frequently exhibit limited efficacy and notable adverse reactions. Therefore, a drug repurposing method is proposed for effective NSCLC treatment.Aims: This study aims to evaluate candidate drugs that are effective for NSCLC at the clinical level using a systems biology and network analysis approach.Methods: Differentially expressed genes in transcriptomics data were identified using the systems biology and network analysis approaches. A network of gene co‐expression was developed with the aim of detecting two modules of gene co‐expression. Following that, the Drug–Gene Interaction Database was used to find possible drugs that target important genes within two gene co‐expression modules linked to non‐small cell lung cancer (NSCLC). The use of Cytoscape facilitated the creation of a drug–gene interaction network. Finally, gene set enrichment analysis was done to validate candidate drugs.Results: Unlike previous research on repositioning drugs for NSCLC, which uses a gene co‐expression network, this project is the first to research both gene co‐expression and co‐occurrence networks. And the co‐occurrence network also accounts for differentially expressed genes in cancer cells and their adjacent normal cells. For effective management of non‐small cell lung cancer (NSCLC), drugs that show higher gene regulation and gene affinity within the drug–gene interaction network are thought to be important. According to the discourse, NSCLC genes have a lot of control over medicines like vincristine, fluorouracil, methotrexate, clotrimazole, etoposide, tamoxifen, sorafenib, doxorubicin, and pazopanib.Conclusion: Hence, there is a possibility of repurposing these drugs for the treatment of non‐small‐cell lung cancer.

1 August 2023 in International Journal of Informatics and Communication Technology (IJ-ICT)
Verified
Journal Article
Open access
PDF file
MSMuhammad Sohaib
Muhammad Sohaib
MAMary Adewunmi
Mary Adewunmi
In this proposed work, we identified the significant research issues on lung cancer risk factors. Capturing and defining symptoms at an early stage is one of the most difficult phases for patients. Based on the history of patients records, we reviewed a number of current research studies on lung cancer and its various stages. We identified that lung cancer is one of the significant research issues in predicting the early stages of cancer disease. This research aimed to develop a model that can detect lung cancer with a remarkably high level of accuracy using the deep learning approach (convolution neural network). This method considers and resolves significant gaps in previous studies. We compare the accuracy levels and loss values of our model with VGG16, InceptionV3, and Resnet50. We found that our model achieved an accuracy of 94% and a minimum loss of 0.1%. Hence physicians can use our convolution neural network models for predicting lung cancer risk factors in the real world. Moreover, this investigation reveals that squamous cell carcinoma, normal, adenocarcinoma, and large cell carcinoma are the most significant risk factors. In addition, the remaining attributes are also crucial for achieving the best performance.

26 August 2021 in ScienceOpen Preprints
Verified
Preprint
Open access
PDF file
MAMary Adewunmi
Mary Adewunmi
Melanoma is the most severe kind of skin cancer that is becoming more common in the Western world. This is still thought to be caused primarily by exposure to the sun. Patients with malignant melanoma have a wide range of prognoses; however public awareness initiatives encouraging early detection have resulted in considerable reductions in mortality rates. This disease primarily affects Caucasian men and women and has a terrible prognosis once it has spread to other parts of the body. As a result, early detection of this malignancy is critical for patient treatment success. In this paper, we present an experimental result of a Melanoma Image Classifier using the VGG16 model for preprocessing the images dataset. Thedataset comprises 4596 image samples with 2239 images for training, 2239 images formodel validationand 118 images for testing the model. The resultant images were trained with a Convolutional Neural Network(CNN) Sequential model of a learning rate of 0.0001,adam optimizer with binary cross-entropy as loss and accuracy as a metric. The model yields an accuracy of 93%, thereby outperforming other Deep learning models. The approach is viable and effective, and it achieves the preliminary goal of classifying melanoma lesion images.

1 January 2024
Verified
Conference Paper
Open access
PDF file
RAReem Abdel‐Salam
Reem Abdel‐Salam
MAMary Adewunmi
Mary Adewunmi
MAMercy Akinwale
Mercy Akinwale
Reem Abdel-salam, Mary Adewunmi, Mercy Akinwale. Proceedings of the 18th International Workshop on Semantic Evaluation (SemEval-2024). 2024.

20 May 2026 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
PSPablo Sanchis
Pablo Sanchis
DADiana C. Aguilar-Cortes
Diana C. Aguilar-Cortes
BKBalachander Kannan
Balachander Kannan
RMRafat Malik
Rafat Malik
JMJoaquin Merlo
Joaquin Merlo
Annie Wai Yeeng ChaiAnnie Wai Yeeng Chai
Annie Wai Yeeng Chai
Cancer is a global disease, yet a paradox persists: The most advanced research ecosystems are concentrated in countries with lower disease burden, whereas low- and middle-income countries (LMIC)—carrying 70% of the global cancer burden—face major constraints in research capacity. Closing this gap is essential for equitable progress in cancer prevention, diagnosis, and treatment. Researchers in LMICs are creatively adapting established technologies, research pipelines, and collaborative models from higher-resource settings to local solutions. In this study, 25 American Association for Cancer Research Global Scholar-in-Training Award recipients from LMICs share how cancer research is advancing within resource-limited settings, focused on (i) infrastructure and resources, (ii) training and talent retention, (iii) funding and sustainability, and (iv) cultural and social barriers. We identified shared challenges and cross-cutting solutions, discussed gaps, and suggested steps to further advancing cancer research. We emphasized locally led innovation, strategic partnerships, and community engagement. These perspectives offer a framework for inclusive, synergistic approaches to strengthening cancer research and accelerating impact where it is needed most.

14 June 2023
Verified
Preprint
Open access
OAOluwatosin Maryam Adeyemo
Oluwatosin Maryam Adeyemo
ZAZainab Ashimiyu-Abdusalam
Zainab Ashimiyu-Abdusalam
MAMary Adewunmi
Mary Adewunmi
TATemitope Ayano
Temitope Ayano
MSMuhammad Sohaib
Muhammad Sohaib
RAReem Abdel-Salam
Reem Abdel-Salam
NSCLC is a highly prevalent cancer and accounts for 85% of cases of lung cancer. Conventional cancer treatments, such as chemotherapy and radiation, frequently exhibit limited efficacy and notable adverse reactions. Therefore, a drug repurposing method is proposed for effective NSCLC treatment. This study aims to evaluate candidate drugs that are effective for NSCLC at the clinical level using systems biology and network analysis approach. Differentially expressed genes of transcriptomics data were identified using the systems biology and network analysis approach. A network of gene co-expression was developed with the aim of detecting two modules of gene co-expression. Subsequently, the Drug-Gene interaction database was employed to pinpoint potential pharmaceutical agents that target crucial genes within two gene co-expression modules associated with non-small cell lung cancer (NSCLC). The construction of a drug-gene interaction network was facilitated with the utilisation of Cytoscape. Finally, the gene set enrichment analysis was done to validate candidate drugs. Unlike previous research on repositioning drugs for NSCLC, which uses a gene co-expression network, this project is the first to research both gene co-expression and co-occurrence networks. And the co-occurrence network also accounts for differentially expressed genes in cancer cells and their adjacent normal cells. Drugs exhibiting elevated gene regulation and gene affinity within the drug-gene interaction network are deemed noteworthy for the efficacious management of non-small cell lung cancer (NSCLC). According to this discourse, NSCLC genes exert a high degree of regulation over medications such as vincristine, fluorouracil, methotrexate, clotrimazole, etoposide, tamoxifen, sorafenib, doxorubicin, and pazopanib. Hence, there is a possibility of repurposing these drugs for the treatment of non-small cell lung cancer. Key words: Non-small cell lung cancer (NSCLC), drug repurposing, network analysis, drug-gene interaction, therapeutics